Safety study of an antibiotic for ABC infection
Part of Infections clinical trials.
This study checks how safe sulbactam-durlobactam (a combination antibiotic) is in adults with a serious infection caused by ABC bacteria, especially looking for allergic reactions. If you are already getting this antibiotic as part of your care, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and staying in the hospital.
- You have or are strongly suspected to have an infection caused by the ABC bacteria.
- You are starting treatment with sulbactam-durlobactam as part of your normal medical care (or started it in the last 24 hours).
- You do not have a history of severe allergic reaction to penicillin-type or similar antibiotics (like amoxicillin or cephalosporins).
- Your doctor expects you to live for more than 48 hours from now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of antibiotics (sulbactam-durlobactam) for children with a serious infection caused by Acinetobacter bacteria. The goal is to see if this treatment is safe and works well for kids.
This study tracks hospitalized patients receiving a specific antibiotic combination (sulbactam-durlobactam) to treat a serious, hard-to-treat bacterial infection called CRAB. Researchers want to understand how well this treatment works in real-world hospital settings.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.